Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Clinical trial NCT07187778 · RECRUITING
Trial details
- NCT number
- NCT07187778
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-19
- Primary completion
- 2027-07-19
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.